Health In Tech Reaffirms 2026 Guidance, Reveals Q2 Loss in Investor Deck
HIT sits 20% above its 52-week low of $0.85.
Summary
Health In Tech furnished an investor presentation showing Q2 revenue down 14% and a net loss of $2.5M, while reaffirming 2026 revenue guidance of $45M–$50M.
Key Events · Earnings and Guidance · HIT
-
Q2 Revenue Declines 14%
Q2 2026 revenue was $8.1M, down from $9.3M in Q2 2025. Gross margin fell to 48.7% from 67.7%.
-
Net Loss Widens
Q2 2026 net loss was $2.5M, compared to net income of $0.6M a year earlier. Adjusted EBITDA was -$1.3M versus +$1.6M.
-
2026 Guidance Reaffirmed
Management reiterated full-year 2026 revenue guidance of $45M–$50M, implying a significant second-half acceleration from the $16.8M reported in 1H 2026.
-
Forward Visibility Metrics
Contracted revenue stood at $32.3M as of June 30, 2026, and pipeline revenue was $66.3M as of July 31, 2026.
Analysis · HIT · Finance
The investor presentation discloses Q2 2026 revenue of $8.1M, down 14% year-over-year, and a net loss of $2.5M, with adjusted EBITDA turning negative at -$1.3M. Gross margin compressed to 48.7% from 67.7% a year earlier. Despite the deterioration, management reaffirmed full-year 2026 revenue guidance of $45M–$50M, implying a significant second-half ramp. The company also highlighted $32.3M in contracted revenue and $66.3M in pipeline revenue, suggesting forward visibility, but the near-term profitability decline and cash balance of $6.5M warrant attention.
At the time of this filing, HIT was trading at $1.02 on NASDAQ in the Finance sector, with a market capitalization of approximately $69.5M. The 52-week trading range was $0.85 to $4.02. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.